1. Home
  2. HCWB vs SPHL Comparison

HCWB vs SPHL Comparison

Compare HCWB & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$1.36

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

HOLD

Current Price

$7.38

Market Cap

3.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCWB
SPHL
Founded
2018
2002
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.5M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
HCWB
SPHL
Price
$1.36
$7.38
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$35.00
N/A
AVG Volume (30 Days)
56.3K
5.6M
Earning Date
11-14-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$422,026.00
$5,956,226.00
Revenue This Year
$178.64
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$1.92
52 Week High
$41.20
$62.40

Technical Indicators

Market Signals
Indicator
HCWB
SPHL
Relative Strength Index (RSI) 44.27 57.94
Support Level $1.10 $2.02
Resistance Level $1.35 $25.11
Average True Range (ATR) 0.13 2.15
MACD 0.06 0.87
Stochastic Oscillator 89.07 24.47

Price Performance

Historical Comparison
HCWB
SPHL

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: